Business Daily Media

Men's Weekly

.

$3M GRANT TO ACCELERATE DEVELOPMENT OF NEUROPLASTOGENS FOR SUBSTANCE USE DISORDER TREATMENT

  • Written by PR Newswire

CRC-P GRANT SECURED BY TESSARA THERAPEUTICS, PSYLO, AND THE UNIVERSITY OF SYDNEY TO ADVANCE BRAIN-REWIRING TREATMENTS FOR ADDICTION

BOULDER, Colo., Oct. 29, 2024 /PRNewswire/ -- Tessara Therapeutics[1], [2]Psylo[3], and the [4]University of Sydney[5] are pleased to announce their receipt of a $3 million [6]Cooperative Research Centres Projects[7] (CRC-P) grant. Matching funds committed by the partners increases the total project investment to $6.2 million. The collaboration will focus on the development of neuroplastogens for the treatment of substance use disorders, with an emphasis on methamphetamine addiction.

Methamphetamine addiction is a serious public health issue with limited effective treatments, highlighting the urgent need for new therapeutic approaches. This collaboration will leverage Tessara's cutting-edge RealBrain® microtissue technology, Psylo's pioneering neuroplastogens, and the University of Sydney's neuroscience expertise to address this critical challenge.

Neuroplastogens are a novel class of compounds that promote neuroplasticity—the brain's capacity to adapt, reorganize, and form new neural connections. Unlike traditional treatments that mainly address symptoms, neuroplastogens aim to directly restore brain function by stimulating the growth and remodeling of neural circuits. This innovative approach has the potential to yield faster, more effective treatments for addiction and other mental health conditions.

"This grant provides an exciting opportunity to combine the expertise of Tessara, Psylo, and the University of Sydney in developing transformative solutions for an urgent medical need," said Dr. Christos Papadimitriou, CEO and Managing Director of Tessara Therapeutics. "Tessara's high-throughput, human cell-based microtissues model brain function more accurately, driving more efficient discovery of drugs to treat addiction."

Joshua Ismin, CEO and co-founder of Psylo, added, "At Psylo, our mission is to address critical gaps in mental health care with next-generation neuroplastogens. This collaboration not only accelerates our drug development but also brings us closer to providing meaningful solutions for addiction-related disorders."

The project aims to significantly reduce the time and cost associated with neuroplastogen discovery, creating faster and more precise pathways for treating substance use disorders.

"This collaboration represents a major step forward in developing research models that better reflect human biology, enabling more precise testing of new therapies," said Dr. Nick Everett, Research Fellow at the Brain and Mind Centre and University of Sydney's School of Psychology, and expert in behavioral neuroscience. "We believe this project could redefine how addiction therapeutics are developed."

Scheduled to run from January 2025 to December 2027, the initiative will not only deliver promising neuroplastogen candidates but also enhance capabilities in neuroplasticity research, improve access to high-efficiency preclinical models, and promote sustainable research practices in drug discovery.

This project received grant funding from the Australian Government under the Cooperative Research Centres Projects Round 16.

About Tessara TherapeuticsTessara Therapeutics[8] is a biotechnology company focused on developing novel drug discovery technologies and therapeutic solutions for mental health disorders. Their innovative approaches aim to revolutionize the preclinical drug development process, improving outcomes and reducing timeframes for new treatments.

About PsyloPsylo[9] is a biotechnology company dedicated to developing next-generation neuroplastogens to treat central nervous system disorders. By utilizing AI-guided drug design and translational biomarkers, Psylo aims to transform the neurotherapeutic landscape and improve the lives of millions worldwide.

About the University of SydneyThe University of Sydney[10] is Australia's first university and a global top-20 higher education teaching and research institution. With world-class programs in neuroscience, psychology, and mental health, the university works in close collaboration with industry to transform how mental health conditions are understood and treated.

 

References

  1. ^ Tessara Therapeutics (www.tessaratherapeutics.com)
  2. ^   (psylo.bio)
  3. ^ Psylo (psylo.bio)
  4. ^   (www.sydney.edu.au)
  5. ^ University of Sydney (www.sydney.edu.au)
  6. ^   (business.gov.au)
  7. ^ Cooperative Research Centres Projects (business.gov.au)
  8. ^ Tessara Therapeutics (www.tessaratherapeutics.com)
  9. ^ Psylo (psylo.bio)
  10. ^ University of Sydney (www.sydney.edu.au)

Read more https://www.prnasia.com/story/archive/4541169_CN41169_0

Demand for Home Batteries surges as Federal Rebate Kicks In

A leading provider of energy solutions VoltX Energy has seen a 400% increase in demand for home batteries in the past three weeks as people put d...

Why Sport Remains the Safest Bet in an Uncertain World

When Rome was in crisis, its leaders did not retreat to the Senate. They went to the circus. To the chariot races. To the gladiators. Sport was no...

THE FINE LINE WITHIN HILARIOUS SIGNAGE DESIGN FAILS

It seems like design failures still occur in today’s modern branding era, despite rigorous rounds of approvals behind the scenes. One signage show...

Deputy Announces Exclusive Global Partnership with Predelo to Bring AI to Shift-Based Businesses

Deputy, the global people platform for shift-based businesses, has announced an exclusive partnership with Predelo, an AI Decision Agent-as-a-Serv...

Leftover Budget? The Last-Minute EOFY Tip to Drive Business Success in FY25/26

The countdown is on. With just days left until EOFY, now’s the time to make your remaining 2024–2025 budget work harder and smarter. After workin...

pay.com.au appoints new CEO and Managing Director

The former COO will lead the company’s next growth phase, with ex-CEO Edward Alder transitioning into the role of Managing Director AUSTRALIA, 25...

Sell by LayBy